866-997-4948(US-Canada Toll Free)

Lung Adenocarcinoma - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Oncology

No. of Pages : 102 Pages


Lung Adenocarcinoma Pipeline Review, H1 2014, provides an overview of the Lung Adenocarcinomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lung Adenocarcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Lung Adenocarcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Lung Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Lung Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Lung Adenocarcinoma Overview 9
Therapeutics Development 10
Pipeline Products for Lung Adenocarcinoma - Overview 10
Pipeline Products for Lung Adenocarcinoma - Comparative Analysis 11
Lung Adenocarcinoma - Therapeutics under Development by Companies 12
Lung Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 14
Lung Adenocarcinoma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Lung Adenocarcinoma - Products under Development by Companies 19
Lung Adenocarcinoma - Products under Investigation by Universities/Institutes 20
Lung Adenocarcinoma - Companies Involved in Therapeutics Development 21
Boehringer Ingelheim GmbH 21
Amgen Inc. 22
Merck & Co., Inc. 23
Takeda Pharmaceutical Company Limited 24
Pfizer Inc. 25
Genmab A/S 26
Immunomedics, Inc. 27
Quantum Pharmaceuticals 28
BioNumerik Pharmaceuticals, Inc. 29
Axelar AB 30
VG Life Sciences, Inc. 31
Medisyn Technologies, Inc. 32
Vichem Chemie Research Ltd. 33
Hanmi Pharmaceuticals, Co. Ltd. 34
Lung Adenocarcinoma - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 40
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
dimesna - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
afatinib - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
dacomitinib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AXL-1717 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
vintafolide - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Cell Therapy to Inhibit CD40L for Metastatic Lung Cancer and Lung Adenocarcinoma - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
poziotinib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
metformin + [bevacizumab] + [carboplatin] + [paclitaxel] - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Stem Cell Therapy for Metastatic Adenocarcinomas - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
solitomab - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SNX-5422 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
hydroxychloroquine + sorafenib tosylate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
MT-477 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Tylophorine Analogs - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Drug to inhibit GATA2 transcriptional targets for Lung Cancer - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecules To Inhibit Phosphofructokinase-2 For Neurodegenerative Diseases And Cancer - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Interferon Lambda-1 Linked Fab Dimer - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
TEMPO-IND - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Lysosomal Acid Ceramidase Inhibitors for Prostate Cancer and Lung Adenocarcinoma - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
TF-011-Monomethyl Auristatin E - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecule Antagonist to PDGFR And VEGFR-2 for Oncology - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
DBPR-112 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
TEMPO-ASA - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule to Inhibit EGFR for Oncology - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Lung Adenocarcinoma - Recent Pipeline Updates 81
Lung Adenocarcinoma - Dormant Projects 96
Lung Adenocarcinoma - Product Development Milestones 97
Featured News & Press Releases 97
Oct 26, 2013: Synta Announces Positive One-Year Follow-up Results for the GALAXY-1 Trial of Ganetespib in NSCLC at the 2013 World Conference on Lung Cancer 97
May 15, 2013: Synta Pharma Announces Presentations On Ganetespib Clinical Trials At 2013 ASCO Annual Meeting 99
Apr 20, 2012: Endocyte Presents Data On Vintafolide At European Lung Cancer Conference 100

Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 102
Disclaimer 102

List of Table


Number of Products under Development for Lung Adenocarcinoma, H1 2014 10
Number of Products under Development for Lung Adenocarcinoma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Products under Development by Companies, H1 2014 19
Products under Investigation by Universities/Institutes, H1 2014 20
Lung Adenocarcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2014 21
Lung Adenocarcinoma - Pipeline by Amgen Inc., H1 2014 22
Lung Adenocarcinoma - Pipeline by Merck & Co., Inc., H1 2014 23
Lung Adenocarcinoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 24
Lung Adenocarcinoma - Pipeline by Pfizer Inc., H1 2014 25
Lung Adenocarcinoma - Pipeline by Genmab A/S, H1 2014 26
Lung Adenocarcinoma - Pipeline by Immunomedics, Inc., H1 2014 27
Lung Adenocarcinoma - Pipeline by Quantum Pharmaceuticals, H1 2014 28
Lung Adenocarcinoma - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2014 29
Lung Adenocarcinoma - Pipeline by Axelar AB, H1 2014 30
Lung Adenocarcinoma - Pipeline by VG Life Sciences, Inc., H1 2014 31
Lung Adenocarcinoma - Pipeline by Medisyn Technologies, Inc., H1 2014 32
Lung Adenocarcinoma - Pipeline by Vichem Chemie Research Ltd., H1 2014 33
Lung Adenocarcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 34
Assessment by Monotherapy Products, H1 2014 35
Assessment by Combination Products, H1 2014 36
Number of Products by Stage and Target, H1 2014 39
Number of Products by Stage and Mechanism of Action, H1 2014 42
Number of Products by Stage and Route of Administration, H1 2014 44
Number of Products by Stage and Molecule Type, H1 2014 46
Lung Adenocarcinoma Therapeutics - Recent Pipeline Updates, H1 2014 81
Lung Adenocarcinoma - Dormant Projects, H1 2014 96

List of Chart


Number of Products under Development for Lung Adenocarcinoma, H1 2014 10
Number of Products under Development for Lung Adenocarcinoma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 35
Assessment by Combination Products, H1 2014 36
Number of Products by Top 10 Target, H1 2014 37
Number of Products by Stage and Top 10 Target, H1 2014 38
Number of Products by Top 10 Mechanism of Action, H1 2014 40
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 41
Number of Products by Top 10 Route of Administration, H1 2014 43
Number of Products by Stage and Top 10 Route of Administration, H1 2014 44
Number of Products by Top 10 Molecule Type, H1 2014 45
Number of Products by Stage and Top 10 Molecule Type, H1 2014 46

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *